Table 2.
Diabetes management of insured adults with diagnosed type 2 diabetes
| Treatment metrics | Total insured | Commercial | Medicare | Medicaid |
|---|---|---|---|---|
| Annual glucose testing | ||||
| % receiving A1c | 82% | 80% | 86% | 64% |
| % receiving FPG | 12% | 10% | 14% | 15% |
| % receiving OGTT | 0.6% | 1.1% | 0.2% | 0.8% |
| Other recommended testing | ||||
| % receiving cholesterol test | 76% | 75% | 81% | 58% |
| % receiving eye exam | NA | 33% | 57% | NA |
| % receiving urinary albumin test | 50% | 45% | 55% | 43% |
| Medication to treat diabetesa | ||||
| % receiving diabetes medication | 77% | 82% | 73% | 75% |
| Receiving diabetes medication | 12,990,000 | 5,930,000 | 5,860,000 | 1,200,000 |
| Receiving metformin | 46% | 53% | 40% | 46% |
| Receiving insulin | 23% | 21% | 23% | 29% |
| Not receiving diabetes medication | 3,900,000 | 1,290,000 | 2,220,000 | 390,000 |
| Receiving other medications | ||||
| ACE inhibitors and ARBsb | 63% | 60% | 67% | 57% |
| Other anti-hypertensives (e.g., diuretics) | 47% | 31% | 62% | 43% |
| Statins | 58% | 55% | 64% | 46% |
| % with hypertension | 80% | 72% | 91% | 61% |
| % with hyperlipidemia | 76% | 75% | 83% | 43% |
Notes: aIncludes insulin, non-insulin injectables, or oral antidiabetic agents
b ACE Angiotensin-converting enzyme inhibitors, ARB Angiotensin II receptor blockers